A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli) in Healthy Female Subjects Aged 18 to 25 Years
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary) ; Hepatitis B vaccine recombinant
- Indications Cervical cancer; Hepatitis B; Human papillomavirus infections
- Focus Pharmacodynamics
- 04 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 21 Feb 2014 Planned End Date changed from 1 Dec 2011 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 21 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.